{{Rsnum
|rsid=2283265
|Gene=DRD2
|Chromosome=11
|position=113414814
|Orientation=minus
|GMAF=0.2117
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
|Gene_s=DRD2
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 71.0 | 25.8 | 3.2
| HCB | 25.0 | 52.3 | 22.7
| JPT | 31.1 | 53.3 | 15.6
| YRI | 82.5 | 17.5 | 0.0
| ASW | 0.0 | 0.0 | 0.0
| CHB | 25.0 | 52.3 | 22.7
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}
{{PMID Auto
|PMID=19772578
|Title=Two-stage case-control association study of dopamine-related genes and migraine
|OA=1
}}

{{PharmGKB
|RSID=rs2283265
|Name_s=
|Gene_s=DRD2
|Feature=
|Evidence=PubMed ID:18077374; PubMed ID:18829695
|Annotation=This variant is in intron 5, and T allele shifts mRNA splicing from the short form (D2S) to the long form (D2L). The T allele carriers are also associated with reduced working memory and attension perfermance.
|Drugs=
|Drug Classes=
|Diseases=Schizophrenia
|Curation Level=Curated
|PharmGKB Accession ID=PA162355757
}}

{{PMID Auto
|PMID=18077373
|Title=Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory.
|OA=1
}}

{{PMID Auto
|PMID=18332877
|Title=Family-based association testing strongly implicates DRD2 as a risk gene for schizophrenia in Han Chinese from Taiwan.
|OA=1
}}

{{PMID Auto
|PMID=19321766
|Title=Dopamine DRD2 polymorphism alters reversal learning and associated neural activity.
|OA=1
}}

{{PMID Auto
|PMID=19393722
|Title=Genetic contributions to avoidance-based decisions: striatal D2 receptor polymorphisms.
|OA=1
}}

{{PMID Auto
|PMID=20179754
|Title=Genetically determined measures of striatal D2 signaling predict prefrontal activity during working memory performance.
|OA=1
}}

{{PMID Auto
|PMID=20617039
|Title=Alcoholism and alternative splicing of candidate genes.
|OA=1
}}

{{PMID Auto
|PMID=21150907
|Title=Intronic polymorphisms affecting alternative splicing of human dopamine D2 receptor are associated with cocaine abuse.
|OA=1
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2283265
|overall_frequency_n=24
|overall_frequency_d=128
|overall_frequency=0.1875
|n_genomes=15
|n_genomes_annotated=0
|n_haplomes=18
|n_articles=0
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23340505
|Title=Dopamine transporter DAT and receptor DRD2 variants affect risk of lethal cocaine abuse: a gene-gene-environment interaction
|OA=1
}}

{{PMID Auto
|PMID=24322206
|Title=Contrasting changes in DRD1 and DRD2 splice variant expression in schizophrenia and affective disorders, and associations with SNPs in postmortem brain
}}

{{PMID Auto
|PMID=22579533
|Title=Binge eating disorder and the dopamine D2 receptor: genotypes and sub-phenotypes.
}}

{{PMID Auto
|PMID=23635803
|Title=ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse.
}}

{{PMID Auto
|PMID=24780147
|Title=Association of dopamine gene variants, emotion dysregulation and ADHD in autism spectrum disorder
}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}